Clifford Chance advises Haier Group on the global regulatory filings for its acquisition of a 20% equity stake in Shanghai RAAS from Grifols

Global law firm Clifford Chance has advised Haier Group on the global regulatory filings for its RMB12.5 billion (approximately US$1.8 billion) acquisition of a 20% equity stake in blood products company Shanghai RAAS from Grifols, S.A.

Lead partner Yong Bai said, “We are pleased to have successfully assisted Haier in this significant investment which expands their portfolio into higher-growth sectors like healthcare. This transaction demonstrates our strong capabilities in navigating the complexity of global regulations, and our commitment to supporting our clients’ growth ambitions.”

Yong was supported by counsel Dayu Man in Hong Kong and trainee lawyer Ziwen Wang in Beijing. The complex transaction also involved lawyers from the firm’s global network, as well as local counsel from multiple jurisdictions, including:

• Washington D.C.: Partners Renee Latour, Timothy Cornell and Brian Concklin, associates Holly Bauer, Erica Hackett and Amber Pirson;
• Madrid: Partners Jaime Almenar and Miguel Odriozola, counsel Begoña Barrantes, senior associate Diego Doménech and lawyer Luisa Morely;
• Barcelona: Senior counsel Carme Briera;
• Paris: Partner Katrin Schallenberg, associates Antoine Réco, Hendrik Coppoolse and Marlen Pezzetta and trainee lawyer Flore Petitot;
• Casablanca: Casablanca Managing Partner Mustapha Mourahib and associate Hasnaa Bennani.

Haier Group is a leading global provider of home appliances and smart home solutions.

Shanghai RAAS is a leading blood products company in China that integrates source plasma collection, blood products research and development, production and sales.